search
Back to results

Armergometry to Improve Mobility in MS (AMBOS)

Primary Purpose

Multiple Sclerosis

Status
Unknown status
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
arm ergometry
Sponsored by
Universitätsklinikum Hamburg-Eppendorf
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Multiple Sclerosis focused on measuring chronic progressive multiple sclerosis, mobility, arm ergometry, rehabilitation

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • proven multiple sclerosis
  • stable disease
  • EDD 4,0-6,5
  • being able to perform arm ergometry

Exclusion Criteria:

  • relapse situation
  • cognitive deficit unable to understand study
  • cardivascular disease
  • contraindication for MRI

Sites / Locations

  • Universitätsklinikum Hamburg-EppendorfRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

arm ergometry

waiting group

Arm Description

Home-based treatment after education in center, training following interval training plan on chip cards for 12 weeks at least 4-5 times/week

training after 12 weeks.

Outcomes

Primary Outcome Measures

6 minute walking test
maximum distance in 6 minutes

Secondary Outcome Measures

accelerometry
walking speed through 7 days
verbal learning and memory
rapid and delayed recall
peak oxygene uptake
at step ergometry
brain atrophy
based on percentage brain volume chnage through 3 months
Brain derived neurotrophic factor
serum levels

Full Information

First Posted
March 2, 2017
Last Updated
May 24, 2017
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Collaborators
Deutsche Multiple Sklerose Gesellschaft Hamburg
search

1. Study Identification

Unique Protocol Identification Number
NCT03147105
Brief Title
Armergometry to Improve Mobility in MS
Acronym
AMBOS
Official Title
Armergometry to Improve Mobility in Chronic Progressive Multiple Sclerosis
Study Type
Interventional

2. Study Status

Record Verification Date
May 2017
Overall Recruitment Status
Unknown status
Study Start Date
May 1, 2017 (Actual)
Primary Completion Date
July 1, 2018 (Anticipated)
Study Completion Date
December 31, 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universitätsklinikum Hamburg-Eppendorf
Collaborators
Deutsche Multiple Sklerose Gesellschaft Hamburg

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Chronic progressive multiple sclerosis patients will be randomised to home-based arm ergometry training for 12 weeks or a waitlist control group which will have access to the treatment after 12 weeks when primary endpoint assessment has been obtained. Assessments include clinical outcomes and questionnaires as well MRI imaging and transcranial magnetic stimulation paradigms. Primary endpoint will be the 6 minute walking test at week 12.
Detailed Description
Short protocol Design: Patients with progressive MS (PPMS, SPMS) and moderate disability (Expanded Disability Status Scale 4-6.5) will be randomized to home-based arm ergometry or a waitlist control group. Home-based training will be supervised by SD-card documentation, telephone, email and personal contact. Inclusion criteria: clinically definite MS according to Poser (1983), no progression in the last 6 months before starting, no acute relapse, age 18- 65 years, EDSS 4-6.5, able to perform all arm- and handfunctions in daily life, able to execute a daily Training. Exclusion criteria: medical contraindications for exercise therapy like cardiovascular or major orthopedic disease, metal parts in body, substantial cognitive deficit, cardiac pacemaker or other electric implants, pregnancy, epilepsy. Recruitment sample: n=50 Participants for analysis: n= 40 Control group: Intervention available after 3 months Duration: 3 months, data acquisition until 12 months after intervention Hypothesis: Arm ergometry improves walking ability (measured by 6-Minute Walk Test, 6MWT). Secondary endpoints include cognition, fatigue, depression, life quality and blood markers as BDNF. Primary endpoint: Walking ability is evaluated before and after the training program (12 weeks) using the 6MWT by measuring the total walking distance within six minutes. Secondary endpoints: Walking abilities: 25FWT, TUG, 5SST, 9HPT, 7-day-accelerometry, MSWS- 12, Walking analysis on Gaitrite tapestry and with kinect camera with different tasks: normal speed, maximal speed, turning around and double tasking EDSS (Expanded Disability status scale) Fitness measures: areobic fitness (peak oxygen consumption VO2), bioimpedance analysis, DIERS-Myoline Muscle Strength Measurement, dynamic hand force measurement, spiroergometry, accelerometry Neuropsychology: Test battery for Attentional Performance (TAP) including alertness, incompatibility and crossmodal integration, Verbal Learning- and Memory- Test (VLMT), Brief International Cognitive Assessment for MS (BICAMS), Symbol- Digit- Modalities Test (SDMT) Questionnaires: HAQUAMS, Fatigue Scale for Motoric and Cognition (FSMC), Beck- Depressions- Inventar (BDI), Frenchay Activity Index (FAI) cMRT Blood: Neurofilament light, BDNF, Analysis with ELISA Intervention: Intervention will be a home-based, individual training with 5 -7 training sessions each week. Each individual training is based on the results of the spiroergometry of the participants. These tests will be conducted at the Competence Center for Sports and Exercise Medicine. The training sessions should be in the areobic exercise sector. In this sector intensity should be conducted at a power, which shows lactate values around 1.5 mmol, RER (Respiratory Exchange Ratio) should be around 0.91 and the subjective stress, measured on Borg-Scale, should be about 11. The V02max should be not higher than 65 %. Before starting the training at home, patients have to come to the center for adaptation to the training machine, the "Motomed". We will test, if the power for the training estimated from stepwise arm ergometry is adeqaute. The patients will recieve an introduction for motomed as well as information on how to handle the chipcards. Patients will get 3 chipcards with one training program on each. The first card contains 10 training sessions. One training range includes 6 minutes active training followed by 2 minute passive rotation by the motomed. Every minute the direction of the crank changes. The frequency should not be higher than 60- 80 U/min. Patients have to repeat one training range (6min load, 2 minute rest) as often as possible. They will recieve one training plan for orientation. After 4 weeks the patients change the chipcard and they start their training with card number 2. Card number 2 includes the same training program as card number 1, but the power increases about 20-30 %. The results of everyday training will be saved automatically on the chipcards. Stored parameters will be heartrate, the power measured in Watt, the length of the training, the number of training ranges, and the frequency on the crank. Furthermore, patients make notes regarding their results and their perceived exertion during the training (measured by Borg-scaling) on a documentation sheet. If the training is too hard, the patients can either train for a shorter time, they can stop the training or they can use the chipcard with the lower power. Procedure: After basline-examinations (walking ability, fitness, neuropsychology, blood draw, questionnaires, cMRT without contrast medium), instruction on "Motomed" and training at center, patients will be provided with the machines at their homes and start their training for 12 weeks under supervision (Email, telephone, home visit). Follow-up will be performed with the same assessments as at baseline including stepwise ergometry. For the assessments 2-3 appointments at the center are necessary.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Sclerosis
Keywords
chronic progressive multiple sclerosis, mobility, arm ergometry, rehabilitation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
waitlist control
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
arm ergometry
Arm Type
Experimental
Arm Description
Home-based treatment after education in center, training following interval training plan on chip cards for 12 weeks at least 4-5 times/week
Arm Title
waiting group
Arm Type
Active Comparator
Arm Description
training after 12 weeks.
Intervention Type
Behavioral
Intervention Name(s)
arm ergometry
Intervention Description
home based arm ergometry, at least 4-5 sessions/week for 12 weeks
Primary Outcome Measure Information:
Title
6 minute walking test
Description
maximum distance in 6 minutes
Time Frame
6 min.
Secondary Outcome Measure Information:
Title
accelerometry
Description
walking speed through 7 days
Time Frame
7 days
Title
verbal learning and memory
Description
rapid and delayed recall
Time Frame
30 minutes
Title
peak oxygene uptake
Description
at step ergometry
Time Frame
20 minutes
Title
brain atrophy
Description
based on percentage brain volume chnage through 3 months
Time Frame
3 months
Title
Brain derived neurotrophic factor
Description
serum levels
Time Frame
3 months change

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: proven multiple sclerosis stable disease EDD 4,0-6,5 being able to perform arm ergometry Exclusion Criteria: relapse situation cognitive deficit unable to understand study cardivascular disease contraindication for MRI
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christoph Heesen, Prof.
Phone
+49407410-0
Ext
-54076
Email
heesen@uke.de
First Name & Middle Initial & Last Name or Official Title & Degree
Manuel Friese, Prof.
Phone
+49407410
Ext
-54076
Email
m.friese@uke.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christoph Heesen, Prof.
Organizational Affiliation
Universitätsklinikum Hamburg-Eppendorf
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universitätsklinikum Hamburg-Eppendorf
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christoph Heesen, Prof.
Phone
+49407410-0
Ext
-54076
Email
heesen@uke.de
First Name & Middle Initial & Last Name & Degree
Andre Mönch
Phone
+49407410-0
Ext
-54076
Email
a.moench@uke.de

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Enclose access to publication
Citations:
PubMed Identifier
34349716
Citation
Heinrich I, Rosenthal F, Patra S, Schulz KH, Welsch GH, Vettorazzi E, Rosenkranz SC, Stellmann JP, Ramien C, Pottgen J, Gold SM, Heesen C. Arm Ergometry to Improve Mobility in Progressive Multiple Sclerosis (AMBOS)-Results of a Pilot Randomized Controlled Trial. Front Neurol. 2021 Jul 19;12:644533. doi: 10.3389/fneur.2021.644533. eCollection 2021.
Results Reference
derived

Learn more about this trial

Armergometry to Improve Mobility in MS

We'll reach out to this number within 24 hrs